Protocols
28 protocol(s) meet the specified criteria
Disease Site: Non-Hodgkins Lymphoma
Protocol No.TitleStatus
14-1999Biomarker-Based Radiation Dosimetry ProjectOpen
ACCL1333A Phase III Randomized, Open Label, Multi-center Study on the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) Treated with Pegylated (PEG) L-AsparaginaseOpen
AMC-083Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies A Trial of the AIDS Malignancy Consortium (AMC)Open
BMA117159A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Subjects with Relapsed/Refractory Multiple Myeloma and Other Advanced Hematologic malignancies Expressing BCMAOpen
BMT-CTN-0702LTContinued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients Who Have Enrolled on BMT CTN 0702 Open
BMT-CTN-1101BMT CTN 1101: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (haplo-BM) for Patients with Hematologic MalignanciesOpen
BMT-CTN-1202Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCTOpen
CALGB50403A Randomized Phase II Trial of Maintenance vs Consolidation Bortezomib Therapy Following Aggresive Chemo-Immunotherapy and Autologous Stem Cell Transplant for Previously Untreated Mantle Cell LymphomaOpen (affiliates only)
CALGB50803A Phase II Trial of Lenalidomide (Revlimid™, CC-5013)(NSC #703813, IND #70116) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin’s Lymphoma (NHL) Open (affiliates only)
CALGB50904A Randomized Phase II Trial of Ofatumumab and Bendamustine Vs. Ofatumumab, Bortezomib (NSC #681239, IND #58443) and Bendamustine in Patients with Untreated Follicular Lymphoma Open (affiliates only)
CC-5013-NHL-008A phase 3b randomized study of lenalidomide (CC-5013) plus rituximab maintenance therapy followed by lenalidomide single-agent maintenance versus rituximab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma.Open (affiliates only)
CLFG316X2202A randomized, open label, controlled, multiple dose study to evaluate the clinical efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of LFG316 in patients with transplant associated microangiopathy after hematopoietic precursor cell transplantationOpen
COG-ACCL1131A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)Open
COG-ANHL12P1A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117Open
GO29383A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA OR ATEZOLIZUMAB ADMINISTERED WITH OBINUTUZUMAB OR TAZEMETOSTAT IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMAOpen
GS-US-339-0102A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects with Relapsed or Refractory Hematologic MalignanciesOpen
LCCC0824Tissue Procurement For Hematolymphoid ConditionsOpen
LCCC0905Graft-Versus-Host Disease Solid Tissue ProcurementOpen
LCCC1229Developing a prospective lymphoma clinical cohort in MalawiOpen
LCCC1314A phase II, placebo-controlled, double-blind, randomized trial of pregabalin for the prophylaxis of granulocyte colony stimulating factor (GCSF)-induced bone painOpen
LCCC1335A Single-Arm Phase II Clinical Trial of Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma in MalawiOpen
LCCC1524-ATLPhase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas after High Dose Therapy and Autologous Stem Transplantation (ATLAS)Open
LCCC1532-ATLPhase Ib/II Study of the Administration of T lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin’s Lymphoma and CD30+ Non-Hodgkin’s LymphomaOpen
LCCC1538Geriatric Assessment Reporting in Real Time (GARRT) in non-electively hospitalized older cancer patients: feasibility, impact, and clinician acceptance.Open
MT-3724-NHL-001-USPharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients with Relapsed non-Hodgkin's B-Cell Lymphoma and B-Cell Chronic Lymphocytic LeukemiaOpen
NCI9534A phase I trial of ibrutinib plus PD 0332991 (palbociclib) in patients with previously treated mantle cell lymphomaOpen
S1001A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-cell Lymphoma (DLBCL) Open (affiliates only)
SGNS40-001SGNS40-001 – A phase 1, open-label, dose-escalation study of SEA-CD40 in adult patients with advanced malignanciesOpen